XPH SPDR Pharmaceuticals ETF


$ 48.82 $ 0.16 (0.33 %)    

Friday, 24-Oct-2025 16:02:02 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 48.72
$ 48.78
$ 47.59 x 3
$ 49.33 x 5
$ 48.68 - $ 48.96
$ 35.06 - $ 49.31
12,187
na
na
$ 0.73
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 trumps-100-drug-tariff-will-hit-americans-economist-says-buyers-eat-the-cost-not-foreign-firms

President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and ...

 mark-cuban-exposes-how-wholesalers-force-pharmacies-into-near-exclusive-deals-detailing-pbms-stranglehold-on-drug-pricing

Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on pres...

 mark-cuban-says-cutting-pbm-fees-wont-reduce-pharmaceutical-rd-funding-manufacturers-can-sell-to-us-for-more

Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for i...

 trumps-pharma-tariffs-can-hit-novo-nordisk-says-barclays-expert-but-its-difficult-to-predict-as-drugmakers-have-complex-supply-chains

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

 trump-threatens-200-pharma-tariffs-but-analyst-says-this-stock-is-immune-and-expected-to-benefit-from-levies

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit&...

 mark-cuban-corrects-elizabeth-warren-as-she-slams-jnj-pfe-for-higher-prices-and-zero-taxes-on-big-pharma-pbms-corrupt-healthcare

A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring d...

Core News & Articles

-Reuters

 trump-sparks-new-chapter-in-transatlantic-trade-war-what-the-us-buys-from-europe

Trump announced 50% tariffs on all EU imports starting June 1, citing high trade deficits and unfair barriers. Pharmaceutical p...

 trumps-drug-price-order-hits-pbms-hardest-cvs-cigna-unh-in-focus-as-experts-highlight-racket-pricing-distortion

Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come und...

 are-your-health-care-etfs-safe-trumps-new-policies-may-trigger-shockwaves-across-pharma-stocks

Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk...

 etf-shake-up-unhs-meltdown-meets-llys-moonshot

Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show...

 eli-lilly-abbvie-bristol-myers-regeneron-and-other-pharma-companies-slide-as-donald-trump-confirms-tariffs-on-pharma-companies

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tar...

 biopharma-a-safe-haven-as-tariff-turmoil-rages-on

Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential...

 perrigo-outlines-2025-growth-plans-projects-sales-boost-and-margin-expansion-by-2027

Perrigo Company shares surged after issuing financial targets for 2025 & 2025-2027 on investor day. Expect sales growth, EP...

 ken-griffins-citadel-places-big-short-bet-against-gsk---heres-what-it-means-for-investors

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent sto...

 purdue-pharma-bankruptcy-plan-rejected-by-supreme-court-billionaire-sacklers-to-face-lawsuits

The Supreme Court has rejected Purdue Pharma's bankruptcy plan, exposing the Sackler family to lawsuits over their role in ...

 organon-beats-on-q1-womens-health-leads-the-charge

Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared.

 here-are-the-best-performing-industry-etfs-and-major-stock-contributors-in-april

It's a good time to look at how the major U.S. stock industry ETFs performed this month, as April comes to an end. In April...

 chevron-uber-technologies-and-a-way-to-bet-against-the-big-guys-are-cnbcs-final-trades

On CNBC’s “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management said that each name is around 3% in t...

 3-pharmaceutical-etfs-that-could-be-due-for-a-rebound

These three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. Support is a large concentr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION